Search

Your search keyword '"Baliellas C"' showing total 75 results
Start Over Author "Baliellas C" Publication Year Range Last 10 years
75 results on '"Baliellas C"'

2. Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C)

Author

Puigvehi, M, Albillos, A, Viu, A, Hernandez-Guerra, M, Vazquez, IF, Prieto, M, Torras, X, Zabal, JMR, Santamaria, LG, Morillas, R, Diago, M, Moron, BDC, Delgado, M, Bonet, L, Turnes, J, Crespo, J, Baliellas, C, Panero, JLC, Badia-Aranda, E, Pascasio, JM, Moreno, JM, Monterde, VB, Carmona, I, Fernandez-Bermejo, M, Quiles, R, Garcia, PB, Gonzalez-Santiago, JM, Gutierrez, ML, Moreno, JJ, Conejero, MDA, De la Vega, J, Escudero-Garcia, D, Arenas, J, and Carrion, JA

Published
2019

4. Survival benefit of liver transplantation in Catalonia: A 2007–13 analysis

Author

Colmenero, J., primary, Lombardo, J., additional, Trota, N., additional, Crespo, G., additional, Bilbao, I., additional, Rafecas, A., additional, Xiol, X., additional, Castells, L., additional, Baliellas, C., additional, Ruiz, P., additional, Biggins, S., additional, Fondevila, C., additional, Tort, J., additional, and Navasa, M., additional

Published
2018
Full Text
View/download PDF

6. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C

Author

Fernández I, Muñoz-Gómez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, Arias A, Prieto M, Castells L, Cuervas-Mons V, Hernández O, Crespo J, Calleja JL, Forns X, and Londoño MC

Subjects
Immunosuppressive therapy, Renal transplantation, Direct-acting antivirals, Hepatitis C, Liver transplant
Abstract

Background & Aims: The development of direct-acting antiviral agents (DAAs) is a major step forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the efficacy and tolerability of DAAs in kidney transplant (KT) recipients. Methods: Hepa-C is a Spanish registry of patients treated with DAAs in which clinical, virological and analytical data were prospectively included. We report on the data from 103 KT recipients who received DAAs. Results: The most commonly used DAAs combinations were sofosbuvir/ledipasvir (n = 59, 57%) and sofosbuvir + daclatasvir (n = 18, 17%). Ribavirin was used in 41% of patients. Sustained viral response after 12 weeks (SVR12) rate was 98%. Grade 2 or 3 anemia appeared in 14 (33%) of patients receiving ribavirin and in 9 (15%) without (p = 0.03). There were three episodes of acute humoral graft rejection. No patient discontinued therapy due to adverse events. Importantly, 57 (55%) patients required immunosuppression dose adjustment. Overall, there were no statistically significant differences in the mean level of serum creatinine, eGFR and proteinuria before and after treatment. Nonetheless, seventeen (16%) patients experienced renal dysfunction (increase in serum creatinine >25%) during antiviral therapy, of whom 65% were cirrhotic in comparison with only 29% cirrhotic patients who did not develop significant renal dysfunction (p = 0.004). Conclusions: Antiviral therapy with DAAs was highly efficacious and safe in KT recipients. Nevertheless, a non-negligible number of patients, most of them cirrhotic, developed mild allograft dys-function and a significant proportion of patients required immunosuppression dose adjustment, warranting a close follow-up during therapy. Lay summary: Infection by hepatitis C virus is often found in kidney transplant patients and its presence increases mortality and graft failure. We investigated the efficacy and safety of the new direct-acting hepatitis C antivirals in this population, in which previous information is scarce. Our data shows that, as occurs in the non-transplant setting, new anti-HCV antivirals are highly efficacious kidney transplant patients. Overall, this therapy is also quite safe, although worsening of renal function is observed in 16% of patients warranting a close follow-up observation of graft function during antiviral therapy. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.

Published
2017

7. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease

Author

Lens, S, Fernandez, I, Rodriguez-Tajes, S, Hontangas, V, Vergara, M, Forne, M, Calleja, JL, Diago, M, Llaneras, J, Llerena, S, Torras, X, Sacristan, B, Roget, M, Fernandez-Rodriguez, CM, Navascues, MC, Fuentes, J, Sanchez-Ruano, JJ, Simon, MA, Saez-Royuela, F, Baliellas, C, Morillas, R, and Forns, X

Abstract

OBJECTIVES: Interferon-free therapies have an improved safety and efficacy profile. However, data in elderly patients, who have frequently advanced liver disease, associated comorbidities, and use concomitant medications are scarce. The im of this study was to assess the effectiveness and tolerability of all-oral regimens in elderly patients in real-life clinical practice. METHODS: Retrospective analysis of hepatitis C virus (HCV) patients aged >= 65 years receiving interferon-free regimens within the Spanish National Registry (Hepa-C). RESULTS: Data of 1,252 patients were recorded. Of these, 955 (76%) were aged 65-74 years, 211 (17%) were aged 75-79 years, and 86 (7%) were aged >= 80 years at the start of antiviral therapy. HCV genotype-1b was predominant (88%) and 48% were previous non-responders. A significant proportion of patients had cirrhosis (922; 74%), of whom 11% presented decompensated liver disease. The most used regimens were SOF/LDV (33%), 3D (28%), and SOF/SMV (26%). Ribavirin was added in 49% of patients. Overall, the sustained virological response (SVR12) rate was 94% without differences among the three age categories. Albumin = 75 years (2.59 (1.16-5.83); P = 0.02) and albumin = 75 years) or those with advanced liver disease (albumin

Published
2017

8. Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort

Author

Riveiro-Barciela, M., Alonso, Sonia, Fernández, Inmaculada, Rincón, Diego, Real, Yolanda, Crespo, Javier, Gea, Francisco, Olveira, Antonio, Calleja, J.L., Polo-Lorduy, B., Carrión, J.A., Arenas, J., Devesa, M.J., Baliellas, C., Castro-Iglesias, Ángeles, Romero-Gómez, Manuel, Granados, R., Pascasio, J.M., Forns, Xavier, Turnes, Juan, Montero, J.L., Esteban, R., and Fernández-Rodríguez, Conrado M.

Subjects
ComputingMethodologies_GENERAL
Abstract

Poster abstract

Published
2016

9. High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry

Author

Aranda, E.B., Mariño, Zoe, Calvo, S., Carrión, J.A., Fernández, I., García-Samaniego, J., Baliellas, C., Pascasio, J.M., Albillos, A., Carrillo, C.F., Castro-Iglesias, Ángeles, Planas, J.M.M., Giner, C.P., Palomares, J.J.M., Llaneras, J., Arenas, J., Fernández-Bermejo, M., Fernández, C., López, R.M.G., García, P.B., Romero-Gómez, Manuel, Sáez-Royuela, F., Aranda, E.B., Mariño, Zoe, Calvo, S., Carrión, J.A., Fernández, I., García-Samaniego, J., Baliellas, C., Pascasio, J.M., Albillos, A., Carrillo, C.F., Castro-Iglesias, Ángeles, Planas, J.M.M., Giner, C.P., Palomares, J.J.M., Llaneras, J., Arenas, J., Fernández-Bermejo, M., Fernández, C., López, R.M.G., García, P.B., Romero-Gómez, Manuel, and Sáez-Royuela, F.

Published
2017

10. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Author

Londoño, M.C., García-Buey, L., Mallolas, J., Barril, Guillermina, Ahumada, A., Riveiro-Barciela, M., Muñoz-Gómez, R., Roget, M., Serra, M.A., Devesa, M.J., Navascues, C., Baliellas, C., Aldamiz-Echevarría, T., Gutiérrez, M.L., Carmona, I., Polo-Lorduy, B., Bonet, L., García-Samaniego, J., Jiménez, M., Prieto, M., Moran, S., Castro-Iglesias, Ángeles, Delgado, M., Gea, F., Martín-Granizo, I., Montes, M., Morano, L., Castaño, M.A., De los Santos, I., Laguno, M., Losa, J.E., Montero, M., Rivero, A., Manzanares, A., De Álvaro, C., Londoño, M.C., García-Buey, L., Mallolas, J., Barril, Guillermina, Ahumada, A., Riveiro-Barciela, M., Muñoz-Gómez, R., Roget, M., Serra, M.A., Devesa, M.J., Navascues, C., Baliellas, C., Aldamiz-Echevarría, T., Gutiérrez, M.L., Carmona, I., Polo-Lorduy, B., Bonet, L., García-Samaniego, J., Jiménez, M., Prieto, M., Moran, S., Castro-Iglesias, Ángeles, Delgado, M., Gea, F., Martín-Granizo, I., Montes, M., Morano, L., Castaño, M.A., De los Santos, I., Laguno, M., Losa, J.E., Montero, M., Rivero, A., Manzanares, A., and De Álvaro, C.

Published
2017

11. Spontaneous bacterial empyem revisited

Author

Amador, A., primary, Berbel, D., additional, Cachero, A., additional, Dueñas, E., additional, García-Guix, M., additional, Salord, S., additional, Rota, R., additional, Baliellas, C., additional, Ardanuy, C., additional, Xiol, X., additional, and Castellote, J., additional

Published
2017
Full Text
View/download PDF

12. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Author

Londoño, M.-C., primary, Garcia-Buey, L., additional, Mallolas, J., additional, Barril, G., additional, Ahumada, A., additional, Riveiro-Barciela, M., additional, Muñoz-Gomez, R., additional, Roget, M., additional, Serra, M.A., additional, Devesa, M.J., additional, Navascues, C., additional, Baliellas, C., additional, Aldamiz-Echevarria, T., additional, Gutierrez, M.L., additional, Carmona, I., additional, Polo-Lorduy, B., additional, Bonet, L., additional, Garcia-Samaniego, J., additional, Jiménez, M., additional, Prieto, M., additional, Moran, S., additional, Castro, A., additional, Delgado, M., additional, Gea, F., additional, Martin-Granizo, I., additional, Montes, M., additional, Morano, L., additional, Castaño, M.A., additional, De los Santos, I., additional, Laguno, M., additional, Losa, J.E., additional, Montero, M., additional, Rivero, A., additional, Manzanares, A., additional, and De Alvaro, C., additional

Published
2017
Full Text
View/download PDF

13. High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry

Author

Aranda, E.B., primary, Mariño, Z., additional, Calvo, S., additional, Carrión, J.A., additional, Fernández, I., additional, García-Samaniego, J., additional, Baliellas, C., additional, Pascasio, J.M., additional, Albillos, A., additional, Carrillo, C.F., additional, Iglesias, A.C., additional, Planas, J.M.M., additional, Giner, C.P., additional, Palomares, J.J.M., additional, Llaneras, J., additional, Arenas, J., additional, Fernández-Bermejo, M., additional, Fernández, C., additional, Lopez, R.M.G., additional, García, P.B., additional, Romero-Gómez, M., additional, and Sáez-Royuela, F., additional

Published
2017
Full Text
View/download PDF

14. Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy

Author

Lens, S., primary, Fernandez, I., additional, Rodríguez-Tajes, S., additional, Vergara, M., additional, Forné, M., additional, Calleja, J.L., additional, Diago, M., additional, Llaneras, J., additional, Llerena, S., additional, Torras, X., additional, Sacristan, B., additional, Roget, M., additional, Fernández-Rodríguez, C.M., additional, Navascués, C., additional, Fuentes, J., additional, Sanchez-Ruano, J.J., additional, Simón, M.A., additional, Saez-Royuela, F., additional, Baliellas, C., additional, Morillas, R.M., additional, and Forns, X., additional

Published
2017
Full Text
View/download PDF

15. Efficacy and safety of HCV-treatment with direct-acting antiviral agents interferon-free, in patients with severe renal impairment in clinical practice

Author

Cabezas, Joaquín, Londoño, M.C., Llerena, S., Muñoz, R., Baliellas, C., Buti, M., Pascasio, J.M., Sáez-Royuela, F., García-Samaniego, J., Vega, J. de la, Sánchez-Pobre, P., Álvarez-Navascues, C., Carrión, J.A., Gea, F., Morillas, R.M., Fernández-Bermejo, M., Castro-Iglesias, Ángeles, Rivero, M., Fernández, J.R., Berenguer, M., Moreno, J.J., Rincón, D., Calleja, J.L., Crespo, J., Cabezas, Joaquín, Londoño, M.C., Llerena, S., Muñoz, R., Baliellas, C., Buti, M., Pascasio, J.M., Sáez-Royuela, F., García-Samaniego, J., Vega, J. de la, Sánchez-Pobre, P., Álvarez-Navascues, C., Carrión, J.A., Gea, F., Morillas, R.M., Fernández-Bermejo, M., Castro-Iglesias, Ángeles, Rivero, M., Fernández, J.R., Berenguer, M., Moreno, J.J., Rincón, D., Calleja, J.L., and Crespo, J.

Published
2016

16. Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4

Author

Mariño, Zoe, Pascasio-Acevedo, Juan M., Sánchez-Antolín, Gloria, Baliellas, C., Prieto, M., Moreno, J.M., Carrión, J.A., Fernández, I., Gómez, A., Montero, J.L., Castro-Iglesias, Ángeles, Pascual, Sonia, Cabezas, Joaquín, Arencibia, Ana C., Calleja, J.L., Sánchez Ruano, Juan José, Castells, Lluis, Albillos, A., Romero-Gómez, Manuel, García-Samaniego, J., Narváez, Isidro, Serrano, T., Giráldez, Álvaro, Xiol, X., Hontagas, V., Cuervas-Mons Martínez, Valentín, Crespo, J., Forns, Xavier, Mariño, Zoe, Pascasio-Acevedo, Juan M., Sánchez-Antolín, Gloria, Baliellas, C., Prieto, M., Moreno, J.M., Carrión, J.A., Fernández, I., Gómez, A., Montero, J.L., Castro-Iglesias, Ángeles, Pascual, Sonia, Cabezas, Joaquín, Arencibia, Ana C., Calleja, J.L., Sánchez Ruano, Juan José, Castells, Lluis, Albillos, A., Romero-Gómez, Manuel, García-Samaniego, J., Narváez, Isidro, Serrano, T., Giráldez, Álvaro, Xiol, X., Hontagas, V., Cuervas-Mons Martínez, Valentín, Crespo, J., and Forns, Xavier

Published
2016

17. Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort

Author

Alonso, S., Riveiro-Barciela, M., Fernández, I., Rincón, D., Real, Y., Llerena, S., Gea, F., Olveira, A., Fernández-Carrillo, C., Polo, B., Carrión, J.A., Gómez, A., Devesa, M.J., Baliellas, C., Castro-Iglesias, Ángeles, Ampuero, J., Granados, R., Pascasio, J.M., Rubín, A., Salmerón, J., Badia, E., Planas, J.M.M., Lens, S., Turnes, J., Montero, J.L., Buti, M., Esteban, R., Fernández-Rodríguez, C.M., Alonso, S., Riveiro-Barciela, M., Fernández, I., Rincón, D., Real, Y., Llerena, S., Gea, F., Olveira, A., Fernández-Carrillo, C., Polo, B., Carrión, J.A., Gómez, A., Devesa, M.J., Baliellas, C., Castro-Iglesias, Ángeles, Ampuero, J., Granados, R., Pascasio, J.M., Rubín, A., Salmerón, J., Badia, E., Planas, J.M.M., Lens, S., Turnes, J., Montero, J.L., Buti, M., Esteban, R., and Fernández-Rodríguez, C.M.

Abstract

[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014‐October 2015). In total, 208 patients were included: 98 (47%) treatment‐experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count <75×10E9/mL (RR: 3.50, P=.019). In patients with MELD <10, type of NS5A inhibitor did not impact on SVR12 (94% vs 97%; adjusted RR: 0.49). Thirteen patients (6.3%) had serious adverse events, including three deaths (1.4%) and one therapy discontinuation (0.5%), higher in decompensated patients (16.7% vs 3.6%, P<.006). In patients with GT3 infection and cirrhosis, SVR12 rates were high with both SOF+DCV and SOF/LDV, with few serious adverse events.

Published
2016

18. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

Author

Alonso, S., primary, Riveiro-Barciela, M., additional, Fernandez, I., additional, Rincón, D., additional, Real, Y., additional, Llerena, S., additional, Gea, F., additional, Olveira, A., additional, Fernandez-Carrillo, C., additional, Polo, B., additional, Carrión, J. A., additional, Gómez, A., additional, Devesa, M. J., additional, Baliellas, C., additional, Castro, Á., additional, Ampuero, J., additional, Granados, R., additional, Pascasio, J. M., additional, Rubín, A., additional, Salmeron, J., additional, Badia, E., additional, Planas, J. M. M., additional, Lens, S., additional, Turnes, J., additional, Montero, J. L., additional, Buti, M., additional, Esteban, R., additional, and Fernández-Rodríguez, C. M., additional

Published
2016
Full Text
View/download PDF

19. Endoscopic radiofrequency ablation for APC refractory gastric antral vascular ectasia using the HALO90 system in a kidney transplant candidate

Author

Ibáñez-Sanz G, Rivas L, Melilli E, Jordi Guardiola, Baliellas C, and Jb, Gornals

Subjects
Male, Argon Plasma Coagulation, Cirurgia, Ronyó, Middle Aged, Kidney, Kidney Transplantation, Ablació percutània, surgical procedures, operative, Gastroscopy, Catheter Ablation, Humans, Kidney Failure, Chronic, Catheter ablation, Surgery, lcsh:Diseases of the digestive system. Gastroenterology, lcsh:RC799-869, Gastric Antral Vascular Ectasia
Abstract

Gastric antral vascular ectasia (GAVE) is a rare but important cause of gastrointestinal bleeding and anemia. Endoscopic ablation, such as argon plasma coagulation (APC), is usually successful, but treatment-refractory cases do occur. Recently, radiofrequency ablation (RFA) has been described as an alternative therapeutic option for GAVE, or actinic proctitis, with positive results and minor complications.

Published
2015

22. Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4

Author

Mariño, Z., primary, Pascasio, J.M., additional, Sánchez-Antolin, G., additional, Baliellas, C., additional, Prieto, M., additional, Moreno, J.M., additional, Carrión, J.A., additional, Fernández, I., additional, Gomez, A., additional, Montero, J.L., additional, Castro, A., additional, Pascual, S., additional, Cabezas, J., additional, Arencibia C. Del, A., additional, Calleja, J.L., additional, Sanchez-Ruano, J.J., additional, Castells, L., additional, Albillos, A., additional, Romero, M., additional, García-Samaniego, J., additional, Narváez, I., additional, Serrano, T., additional, Giraldez, A., additional, Xiol, X., additional, Hontangas, V., additional, Cuervas-Mons, V., additional, Crespo, J., additional, and Forns, X., additional

Published
2016
Full Text
View/download PDF

25. Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C)

Author

Londoño, M.-C., primary, Fernández, I., additional, Muñoz-Gómez, R., additional, Pascasio, J.-M., additional, Baliellas, C., additional, Polanco, N., additional, Esforzado, N., additional, Prieto, M., additional, Castells, L., additional, Crespo, J., additional, Calleja, J.-L., additional, Gea, F., additional, and Forns, X., additional

Published
2016
Full Text
View/download PDF

26. Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience

Author

Prieto, M., primary, Fernández, I., additional, Londoño, M.-C., additional, Abradelo, M., additional, Pascasio, J.M., additional, Gea, F., additional, Rincón, D., additional, Cuervas-Mons, V., additional, Crespo, G., additional, Montero, J.L., additional, Hontangas, V., additional, Baliellas, C., additional, Sousa, J.M., additional, García, M., additional, Pascual, S., additional, Pons, J.A., additional, Castells, L., additional, Testillano, M., additional, Jimenez, M., additional, Otero, A., additional, Molina, E., additional, González, A., additional, Nogueras, F., additional, González-Dieguez, L., additional, Lorente, S., additional, Sánchez-Antolín, G., additional, Herrero, J.I., additional, and Casafont, F., additional

Published
2016
Full Text
View/download PDF

27. Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry

Author

Fernández-Carrillo, C., primary, Lens, S., additional, Llop, E., additional, Pascasio, J.M., additional, Fernández, I., additional, Baliellas, C., additional, Crespo, J., additional, Buti, M., additional, Castells, L., additional, Romero-Gómez, M., additional, Pons, C., additional, Moreno, J.M., additional, Albillos, A., additional, Fernández-Rodríguez, C., additional, Prieto, M., additional, Fernández-Bermejo, M., additional, García-Samaniego, J., additional, Carrión, J.A., additional, de la Mata, M., additional, Badia, E., additional, Salmerón, J., additional, Herreros, J.I., additional, Salcedo, M., additional, Moreno, J.J., additional, Turnes, J., additional, Granados, R., additional, Blé, M., additional, and Calleja, J.L., additional

Published
2016
Full Text
View/download PDF

29. Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice

Author

Cabezas, J., primary, Londoño, M.C., additional, Llerena, S., additional, Muñoz, R., additional, Baliellas, C., additional, Buti, M., additional, Pascasio, J.M., additional, Saez-Royuela, F., additional, García-Samaniego, J., additional, de la Vega, J., additional, Sanchez-Pobre, P., additional, Alvarez-Navascues, C., additional, Carrión, J.A., additional, Gea, F., additional, Morillas, R.M., additional, Fernandez-Bermejo, M., additional, Castro, A., additional, Rivero, M., additional, Fernandez, J.R., additional, Berenguer, M., additional, Moreno, J.J., additional, Rincon, D., additional, Calleja, J.L., additional, and Crespo, J., additional

Published
2016
Full Text
View/download PDF

31. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.

Author

Alonso, S., Riveiro‐Barciela, M., Fernandez, I., Rincón, D., Real, Y., Llerena, S., Gea, F., Olveira, A., Fernandez‐Carrillo, C., Polo, B., Carrión, J. A., Gómez, A., Devesa, M. J., Baliellas, C., Castro, Á., Ampuero, J., Granados, R., Pascasio, J. M., Rubín, A., and Salmeron, J.

Subjects
TREATMENT of cirrhosis of the liver, HEPATITIS C treatment, SOFOSBUVIR, MEDICATION safety, DRUG efficacy, GENOTYPES
Abstract

Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014-October 2015). In total, 208 patients were included: 98 (47%) treatment-experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count <75×10E9/mL (RR: 3.50, P=.019). In patients with MELD <10, type of NS5A inhibitor did not impact on SVR12 (94% vs 97%; adjusted RR: 0.49). Thirteen patients (6.3%) had serious adverse events, including three deaths (1.4%) and one therapy discontinuation (0.5%), higher in decompensated patients (16.7% vs 3.6%, P<.006). In patients with GT3 infection and cirrhosis, SVR12 rates were high with both SOF+DCV and SOF/LDV, with few serious adverse events. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. SAT-266 - Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy

Author

Lens, S., Fernandez, I., Rodríguez-Tajes, S., Vergara, M., Forné, M., Calleja, J.L., Diago, M., Llaneras, J., Llerena, S., Torras, X., Sacristan, B., Roget, M., Fernández-Rodríguez, C.M., Navascués, C., Fuentes, J., Sanchez-Ruano, J.J., Simón, M.A., Saez-Royuela, F., Baliellas, C., Morillas, R.M., and Forns, X.

Published
2017
Full Text
View/download PDF

33. SAT-226 - Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Author

Londoño, M.-C., Garcia-Buey, L., Mallolas, J., Barril, G., Ahumada, A., Riveiro-Barciela, M., Muñoz-Gomez, R., Roget, M., Serra, M.A., Devesa, M.J., Navascues, C., Baliellas, C., Aldamiz-Echevarria, T., Gutierrez, M.L., Carmona, I., Polo-Lorduy, B., Bonet, L., Garcia-Samaniego, J., Jiménez, M., Prieto, M., Moran, S., Castro, A., Delgado, M., Gea, F., Martin-Granizo, I., Montes, M., Morano, L., Castaño, M.A., De los Santos, I., Laguno, M., Losa, J.E., Montero, M., Rivero, A., Manzanares, A., and De Alvaro, C.

Published
2017
Full Text
View/download PDF

34. THU-275 - High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry

Author

Aranda, E.B., Mariño, Z., Calvo, S., Carrión, J.A., Fernández, I., García-Samaniego, J., Baliellas, C., Pascasio, J.M., Albillos, A., Carrillo, C.F., Iglesias, A.C., Planas, J.M.M., Giner, C.P., Palomares, J.J.M., Llaneras, J., Arenas, J., Fernández-Bermejo, M., Fernández, C., Lopez, R.M.G., García, P.B., Romero-Gómez, M., and Sáez-Royuela, F.

Published
2017
Full Text
View/download PDF

36. Direct‐acting antivirals are effective and safe in HCV/HIV‐coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

Author

Manzardo, Christian, Londoño, Maria C., Castells, LLuís, Testillano, Milagros, Luis Montero, José, Peñafiel, Judit, Subirana, Marta, Moreno, Ana, Aguilera, Victoria, Luisa González‐Diéguez, María, Calvo‐Pulido, Jorge, Xiol, Xavier, Salcedo, Magdalena, Cuervas‐Mons, Valentin, Manuel Sousa, José, Suarez, Francisco, Serrano, Trinidad, Ignacio Herrero, Jose, Jiménez, Miguel, Fernandez, José R., Giménez, Carlos, del Campo, Santos, Esteban‐Mur, Juan I., Crespo, Gonzalo, Moreno, Asunción, de la Rosa, Gloria, Rimola, Antoni, Miro, Jose M., Suárez, F., Castro, M.A., López, S., Pedreira, J.D., Vázquez, P., Agüero, F., Blanch, J., Brunet, M., Calatayud, D., Cervera, C., Lazzari, E., Fondevila, C., Forner, A., Fuster, J., Forns, X., Gil, A., Gatell, J.M., Laguno, M., Lligoña, A., Mallolas, J., Murillas, J., Navasa, M., Paredes, D., Pérez, I., Torres, F., Tural, C., Tuset, M., Antela, A., Losada, E., Molina, E., Otero, E., Varo, E., Araiz, J.J, Barrao, E., Larraga, J., Letona, S., Lozano, R., Luque, P., Navarro, A., Sanjoaquín, I., Tejero, E., Bañares, R., Berenguer, J., Clemente, G., Cosín, J., Ferreiroa, J.P, García‐Sabrido, J.L., Gutiérrez, I., López, J.C., Miralles, P., Ramírez, M., Rincón, D., Sánchez, M., Cruz, J., Fernández, J.L., Lozano, J.M., Santoyo, J., Rodrigo, J.M., Suárez, M.A., Rodríguez, M., Alonso, M.P., Asensi, V., González‐Pinto, I., Rafecas, A., Baliellas, C., Carratalá, J., Fabregat, J., Fernández, N., Jorba, R., Lladó, L., Montejo, M., Bustamante, J., Fernández, J.R., Gastaca, M., González, J., Montejo, E., Ortiz de Urbina, J., Ruiz, P., Suárez, M.J., Valdivieso, A., Ventoso, A., Abradelo, M., Calvo, J., Costa, J.R., García‐Sesma, A., Jiménez, C., Manrique, A., Meneu, J.C., Moreno, E., Moreno, V., Olivares, S.P., Pulido, F., Rubio, R., Blanes, M., Berenguer, M., López, J., López, R., Prieto, M., Fariñas, M.C., Casafont, F., Echevarria, S., Fábrega, E., Gomez‐Fleitas, M., Armiñanzas, C., Herrera‐Noreña, J.L., Moreno, S., Barcena, R., Fortún, J., Moreno, A.M., Martín‐Dávila, P., Torre‐Cisneros, J., Barrera, P., Briceño, J., Caston, J.J., Costan, G., Mata, M., Lara, R., López‐Cillero, P., Rivero, A., Rufian, S., Sánchez‐Antolín, G., García Pajares, F., Bachiller, P., Almohalla, C., Barrera, A., Conde, R., Bilbao, I., Campos‐Varela, I., Charco, R., Esteban, J.I., Gavaldá, J., Len, O., Pahissa, A., Ribera, E., Vargas, V., Pons, J.A., Cordero, E., Bernal, C., Cisneros, J.M., Gómez, M.A., Pascasio, J.M., Rodríguez, M.J., Sayago, M., Suárez, G., González‐García, J., Aznar, E., Esteban, H., Moyano, B., Garrido, G., Mahillo, B., Matesanz, R., Guerra, L., Manzanera, M., and Samuel, D.

Abstract

Direct‐acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV‐coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV‐coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV‐monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV‐coinfected patients had a median (IQR) CD4 T‐cell count of 366 (256‐467) cells/µL. HIV‐RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV‐RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P= .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P= .093) and genotype 4 (P= .088) was observed. In conclusion, interferon‐free regimens with DAAs for post‐LT recurrence of HCV infection in HIV‐infected individuals were highly effective and well tolerated, with results comparable to those of HCV‐monoinfected patients. Direct‐acting antivirals against HCV offer a very high and similar efficacy and safety in HIV‐positive and HIV‐negative liver transplant recipients.

Published
2018
Full Text
View/download PDF

37. SAT-286 - Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4

Author

Mariño, Z., Pascasio, J.M., Sánchez-Antolin, G., Baliellas, C., Prieto, M., Moreno, J.M., Carrión, J.A., Fernández, I., Gomez, A., Montero, J.L., Castro, A., Pascual, S., Cabezas, J., Arencibia C. Del, A., Calleja, J.L., Sanchez-Ruano, J.J., Castells, L., Albillos, A., Romero, M., García-Samaniego, J., Narváez, I., Serrano, T., Giraldez, A., Xiol, X., Hontangas, V., Cuervas-Mons, V., Crespo, J., and Forns, X.

Published
2016
Full Text
View/download PDF

38. GS01 - Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry

Author

Fernández-Carrillo, C., Lens, S., Llop, E., Pascasio, J.M., Fernández, I., Baliellas, C., Crespo, J., Buti, M., Castells, L., Romero-Gómez, M., Pons, C., Moreno, J.M., Albillos, A., Fernández-Rodríguez, C., Prieto, M., Fernández-Bermejo, M., García-Samaniego, J., Carrión, J.A., de la Mata, M., Badia, E., Salmerón, J., Herreros, J.I., Salcedo, M., Moreno, J.J., Turnes, J., Granados, R., Blé, M., and Calleja, J.L.

Published
2016
Full Text
View/download PDF

40. SAT-209 - Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience

Author

Prieto, M., Fernández, I., Londoño, M.-C., Abradelo, M., Pascasio, J.M., Gea, F., Rincón, D., Cuervas-Mons, V., Crespo, G., Montero, J.L., Hontangas, V., Baliellas, C., Sousa, J.M., García, M., Pascual, S., Pons, J.A., Castells, L., Testillano, M., Jimenez, M., Otero, A., Molina, E., González, A., Nogueras, F., González-Dieguez, L., Lorente, S., Sánchez-Antolín, G., Herrero, J.I., and Casafont, F.

Published
2016
Full Text
View/download PDF

41. SAT-179 - Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice

Author

Cabezas, J., Londoño, M.C., Llerena, S., Muñoz, R., Baliellas, C., Buti, M., Pascasio, J.M., Saez-Royuela, F., García-Samaniego, J., de la Vega, J., Sanchez-Pobre, P., Alvarez-Navascues, C., Carrión, J.A., Gea, F., Morillas, R.M., Fernandez-Bermejo, M., Castro, A., Rivero, M., Fernandez, J.R., Berenguer, M., Moreno, J.J., Rincon, D., Calleja, J.L., and Crespo, J.

Published
2016
Full Text
View/download PDF

45. Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients.

Author

Nedkova-Hristova V, Donadeu L, Baliellas C, González-Costello J, Lladó L, González-Vilatarsana E, Vélez-Santamaría V, de la Prida MM, Bestard O, and Casasnovas C

Abstract

Introduction: Acquired amyloid neuropathy is an iatrogenic disease that appears years after a domino liver transplant. The objectives of our study are to analyze the efficacy and tolerability of tafamidis for the treatment of acquired amyloid neuropathy in domino liver transplant recipients. This post-authorization, prospective, longitudinal study included seven domino liver transplant recipients with acquired amyloid neuropathy who received treatment with tafamidis for 18 months., Methods: The primary endpoints were the response rate, defined as those patients with an increase of < 2 points on the Neurological Impairment Score (NIS) from baseline, and the change in the NIS score from baseline. Secondary endpoints included the Quantitative Sensory Test, 10-m walk test, quality of life (Norfolk), and disability (Rasch-built Overall Disability Scale). As safety parameters, the evidence of graft rejection, changes in immunosuppressive trough levels and changes in antiviral and allogeneic cellular immunity before and 12 months after tafamidis treatment were also assessed., Results: Six patients (85.7%) had responded at 18-months. Compared to baseline, we observed non-statistically significant improvement in mean NIS score at 6 months (- 2.54 points, CI - 5.92 to 0.84), 12 months (- 3.25 points; CI - 6.63 to 0.13), and 18 months (- 2.35 points; CI - 5.74 to 1.02). Changes in the Quantitative Sensory Test, 10-m walk tests and the quality of life and disability questionnaires were not statistically significant. The use of tafamidis did not induce relevant side effects or drug interactions. Also, no acute rejections events nor changes in functional adaptive immunity were observed., Conclusion: Our study supports the safety and tolerability of tafamidis for the treatment of acquired amyloid neuropathy in domino liver transplant recipients. Tafamidis shows promise as a useful treatment in the clinical management of these patients. Future randomized placebo-controlled clinical trials with longer follow-up durations are needed., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

46. Improvement of quality of care provided to outpatients with hepatic cirrhosis after an educational intervention.

Author

Amador A, Salord S, Xiol X, Garcia-Guix M, Cachero A, Rota R, Hernandez Aretxabaleta N, Baliellas C, and Castellote J

Subjects
Humans, Female, Male, Cross-Sectional Studies, Middle Aged, Aged, Liver Neoplasms therapy, Esophageal and Gastric Varices etiology, Esophageal and Gastric Varices therapy, Esophageal and Gastric Varices prevention & control, Carcinoma, Hepatocellular therapy, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage prevention & control, Spain, Vaccination, Severity of Illness Index, Ambulatory Care standards, Guideline Adherence, Patient Education as Topic standards, Liver Cirrhosis complications, Liver Cirrhosis therapy, Quality Indicators, Health Care, Quality Improvement
Abstract

Objective: A set of indicators has been reported to measure the quality of care for cirrhotic patients, and previously published studies report variable adherence rates to these indicators. This study aimed to assess the quality of care provided to cirrhotic outpatients before and after an educational intervention by determining its impact on adherence to quality indicators., Methods: We conducted a quasi-experimental, cross-sectional study including 324 cirrhotic patients seen in 2017 and 2019 at a tertiary teaching hospital in Spain. Quality indicators were assessed in five domains: documentation of cirrhosis etiology, disease severity assessment, hepatocellular carcinoma (HCC) screening, variceal bleeding prophylaxis, and vaccination. After identifying areas for improvement, an educational intervention was implemented. A second evaluation was performed after the intervention to assess changes in adherence rates., Results: Before the intervention, adherence rates were excellent (>90%) for indicators related to variceal bleeding prophylaxis and documentation of cirrhosis etiology, acceptable (60-80%) for HCC screening and disease severity assessment, and poor (<50%) for vaccinations. After the educational intervention, there was a statistically significant improvement in adherence rates for eight indicators related to HCC screening (70-90%), disease severity assessment (90%), variceal bleeding prophylaxis (>90%), and vaccinations (60-90%)., Conclusion: Our study demonstrates a significant improvement in the quality of care provided to cirrhotic outpatients after an educational intervention. The findings highlight the importance of targeted educational interventions to enhance adherence to quality indicators in the management of cirrhosis., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

47. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.

Author

Rodríguez-Tajes S, García-Eliz M, Marcos AC, Campos-Varela I, Ros AC, Loinaz C, Gómez Bravo MÁ, Rodríguez-Perálvarez M, Fabrega E, González Diéguez ML, Vinaixa C, Pascasio JM, Vázquez IF, Baliellas C, Castells L, Salcedo M, Prieto M, Crespo G, Lens S, and Forns X

Subjects
Humans, Antiviral Agents therapeutic use, Hepatitis B Surface Antigens, Treatment Outcome, Liver Cirrhosis complications, Liver Cirrhosis surgery, Liver Cirrhosis drug therapy, Immunoglobulins therapeutic use, Recurrence, Hepatitis B virus genetics, Liver Transplantation
Abstract

Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used., (© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

48. Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study.

Author

Caballero-Marcos A, Peligros I, Pérez-Rojas J, Campos-Varela I, Colmenero J, Gómez-Bravo MÁ, Justo I, Otero A, Molina-Pérez E, González-Diéguez L, Baliellas C, Romero-Cristobal M, Aguilera V, Castells L, Díaz A, Marín-Gómez LM, Loinaz C, Bañares R, and Salcedo M

Subjects
Humans, Hepatic Veno-Occlusive Disease diagnosis, Hepatic Veno-Occlusive Disease etiology, Liver Transplantation adverse effects
Published
2022
Full Text
View/download PDF

49. Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study.

Author

Roche B, Bauhofer A, Gomez Bravo MÃ, Pageaux GP, Zoulim F, Otero A, Prieto M, Baliellas C, and Samuel D

Subjects
Adult, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Female, Humans, Immunoglobulins therapeutic use, Male, Neoplasm Recurrence, Local etiology, Patient Reported Outcome Measures, Prospective Studies, Quality of Life, Recurrence, Reinfection, Treatment Outcome, Carcinoma, Hepatocellular etiology, Hepatitis B drug therapy, Hepatitis B prevention & control, Liver Neoplasms etiology, Liver Transplantation adverse effects
Abstract

BACKGROUND Self-administered subcutaneous hepatitis B immunoglobulin (s.c. HBIg) in combination with nucleos(t)ide analogs (NUCs) has proved to be effective and safe in preventing hepatitis B virus (HBV) reinfection after liver transplantation. MATERIAL AND METHODS This non-interventional, prospective, single-arm, multicenter, international study collected data on long-term effectiveness, safety, patient satisfaction (Treatment Satisfaction Questionnaire for Medication, TSQM-11), and quality of life (EQ-5D questionnaire) in routine practice over a 2-year treatment period. Data analysis was based on 195 adults (82.1% male) transplanted for HBV-related liver diseases and treated with s.c. HBIg with/without NUC(s). RESULTS HBV recurrence (seropositivity of HBV surface antigen and/or HBV DNA) was observed in 7/195 (3.6%) patients (annual rate: 2.01%). Hepatocellular carcinoma (HCC) recurred in 4/83 (4.8%) patients transplanted for HBV-HCC (annual rate: 2.88%). Twenty-nine adverse drug reactions occurred in 16/195 (8.2%) patients. Convenience and overall satisfaction scores of the TSQM-11 were significantly (P<0.05) improved under treatment at the 3-month, 2-year, and last follow-up visits. Quality of life remained constant over the entire observation period (EQ-5D index [P≥0.075]). S.c. HBIg was mainly self-administered (6458/9021 administrations, 71.6%) at home (8514/9021 administrations, 94.4%). CONCLUSIONS The results indicate long-term effectiveness and safety of s.c. HBIg in combination with NUC therapy in preventing post-transplant HBV reinfection under real-life conditions. The convenience of the therapy contributed to the high overall treatment satisfaction and acceptance by the patients.

Published
2022
Full Text
View/download PDF

50. Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy.

Author

Nedkova-Hristova V, Baliellas C, González-Costello J, Lladó L, González-Vilatarsana E, Vélez-Santamaría V, and Casasnovas C

Subjects
Humans, Longitudinal Studies, Retrospective Studies, Transplant Recipients, Amyloid Neuropathies, Diflunisal therapeutic use
Abstract

Objectives: To analyze the efficacy and tolerability of diflunisal for the treatment of acquired amyloid neuropathy in domino liver transplant recipients. Methods: We performed a retrospective longitudinal study of prospectively collected data for all domino liver transplant recipients with acquired amyloid neuropathy who received diflunisal at our hospital. Neurological deterioration was defined as an score increase of ≥2 points from baseline on the Neurological Impairment Scale/Neurological Impairment Scale-Lower Limbs. Results: Twelve patients who had received compassionate use treatment with diflunisal were identified, of whom seven had follow-up data for ≥12 months. Five patients (71.4%) presented with neurological deterioration on the Neurological Impairment Scale after 12 months ( p = 0.0382). The main adverse effects were cardiovascular and renal, leading to diflunisal being stopped in five patients and the dose being reduced in two patients. Conclusion: Our study suggests that most domino liver transplant recipients with acquired amyloid neuropathy will develop neurological deterioration by 12 months of treatment with diflunisal. This therapy was also associated with a high incidence of adverse effects and low treatment retention. The low efficacy and low tolerability of diflunisal treatment encourage the search for new therapeutic options., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Nedkova-Hristova, Baliellas, González-Costello, Lladó, González-Vilatarsana, Vélez-Santamaría and Casasnovas.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results